




Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review

Dorota Matecka, Ph.D.
Office of New Drug Quality Assessment, CDER

Outline

- Pharmaceutical Quality
- CMC Requirements for INDs
- CMC Safety Concerns
- Impurities
- Other Considerations (QbD)
- IND Guidance Sources
- Summary

Pharmaceutical Quality



The challenge for the Quality review and inspection for a New Drug Application is to assure that the characteristics and performance of the clinical batches will be replicated consistently in the commercial batches

Drug Substance and Drug Product

- Drug Substance (Active Pharmaceutical Ingredient, API)
 - An **active ingredient**, intended for incorporation into a finished dosage form, that meets the statutory definition of a drug (i.e., that is **intended to furnish pharmacological activity or other direct effect** in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body)
- Drug Product
 - A **finished dosage** form (e.g., tablet, capsule, or solution) that contains a drug substance, generally but not necessarily in association with one or more other ingredients

21 CFR 314.3 Definitions

Investigator Brochure CMC

21 CFR 312.23(a)(5) Investigator's brochure.

If required under § 312.55, a copy of the investigator's brochure, containing the following information:

- (i) A brief description of the drug substance and the formulation, including the structural formula, if known.

IND Regulation

- 21 CFR 312.23(a)(7)(i)
 - As appropriate for the particular investigations covered by the IND, a section describing the composition, manufacture, and control of the drug substance and the drug product.....
 - sufficient CMC information to assure the proper **identification, quality, purity and strength** of the investigational drug

Identity

- The **structure** of the Drug Substance (API) **must be proven** and controls must be used in the manufacturing process to ensure that the same structure is obtained in every batch
- The types of techniques or combination of techniques that may be required to fully elucidate the structure depends on the nature of the drug substance

Strength (Potency/Assay)

The drug product needs to contain the required amount of drug substance

- Assay of the Drug Substance
 - Validated stability-indicating assay or bioassay
- Assay of the Drug Product
 - Validated stability-indicating assay or bioassay (assay needs to be selective for the drug substance without interference from excipients, impurities, or degradants)
- Well-controlled manufacturing processes
- In-Process Blend Uniformity
- Uniformity of Dosage Units
- Container/Closure (Adsorption/Absorption)
- Stability (Expiration Dating Period)

Purity

- Chemical purity
(process impurities, degradation products, leachables from container closure system, etc.)
- Microbiological purity
(microbial limits; absence of specific microorganisms, etc.)

CMC Regulatory Requirements

[21 CFR312.23(a)(7)]

- Regulations emphasize the graded nature of CMC information needed as drug development progresses under an IND
- The amount of information needed depends on
 - Phase of investigation
 - Dosage form
 - Duration of study
 - Patient population
 - Amount of information otherwise available
- The emphasis in an initial **Phase 1** CMC submission should generally be placed on providing information that will allow evaluation of the **safety of subjects** in the proposed study

Drug Substance Requirements for INDs

- Description and characterization
- Manufacturer (name, address, contact information)
- General method of preparation/synthesis
- Specification (tests, analytical procedures and acceptance criteria)
- Batch analysis data for clinical trial batch
- Stability (through end of clinical trial)

Drug Product Requirements for INDs

- Components
 - Novel excipients may require additional information
- Quantitative composition
- Manufacturer (name, address, contact information)
- Description of manufacturing and packaging process
- Container/closure system
- Specification (tests, analytical procedures and acceptance criteria)
- Stability (through end of clinical trial)

Other Drug Product Requirements

- Labels and labeling – mock-up labels
 - Caution statement that reads: “Caution: New Drug Limited by Federal (or United States) law to investigational use.”
- Environmental Assessment
 - Claim for a categorical exclusion
- Placebo information

CMC Safety Concerns

- **Potential safety issues for drug substance**
 - Not well characterized
 - Not well controlled (e.g. assay, impurities, residual solvents)
 - Impurities that are structural alerts (e.g. genotoxic)
 - Lack of stability (e.g., degradation impurities) to support clinical duration
 - Lack of comparative assessment clinical vs. pre-clinical drug substance so as to link safety.
- **Potential safety issues for drug product**
 - Formulation – composition (such as excipients)
 - Dosage form and route of administration
 - Controls/specifications (safety)
 - Stability of formulation, packaging compatibility, in-use, etc.

CMC Safety Concerns (potential “hold” issues)

- Generally
 - Impurities
 - Overdose
- For parenteral products
 - Sterility
 - Endotoxins
 - Particulates

What is an impurity?


- Any component of the new drug substance that is not the chemical entity defined as the new drug substance (ICH Q3A)
- Any component of the drug product that is not the drug substance or an excipient in the drug product (ICH Q3B)

Impurities*


- Drug substance impurities
 - Organic impurities (process- and drug related, e.g., starting materials, by-products, intermediates, degradation products, reagents, catalysts)
 - Inorganic impurities (heavy metals or other residual metals, inorganic salts)
 - Residual solvents, polymorphic forms, enantiomeric impurities, extraneous contaminants
- Drug product impurities
 - Degradation products of the drug substance
 - Reaction products of the drug substance with excipients and/or with immediate container/ closure system

* Special considerations for potential or known [genotoxic impurities](#)

Impurities More Toxic than Drug



Desmethyprodine
an opioid analgesic



MPTP

causes chronic irreversible
Parkinsonian symptoms

Quality by Design - QbD

Design product with
patient in mind:
Quality Target Product
Profile (QTPP)



Rational Design of
Manufacturing
Process

Understand Product:
Critical Quality Attributes (CQA)


Understand Process
Manufacturing Parameters ↔ CQA

Mapping the Linkage

Inputs:



Outputs:



Relationships:
 CQA1 = function (M1)
 CQA2 = function (P1, P3)
 CQA3 = function (M1, M2, P1)

Drug Product Specification

Attribute	Acceptance Criteria (typical values)	Analytical Procedure (for example)
Identity	Matches Standard	IR or HPLC/UV
Appearance	Color, Imprint	Visual
Assay	90-110%	HPLC
Dose Uniformity	Statistical Criterion (USP)	HPLC or Weight
Release from Dosage Form	80% in 15 or 30 minutes	Stirred Aqueous Vessel
Impurities (Related Substances)	<1% to few %	HPLC
Microbial Limits Or Sterility	# of total aerobes and fungi per gram Pathogen (-)	Growth in special media
Water Content	Few %	Chemical or wgt. loss
Preservative Content	NLT 75% of Initial	HPLC


Drug Substance Specification

Attribute	Acceptance Criteria (typical values)	Analytical Procedure (for example)
Identity	Matches Standard	IR or HPLC/UV
Assay	98-102%	HPLC
Appearance	Color	Visual
Impurities (Related Substances)	<1% to few %	HPLC
Inorganic Impurities	Heavy Metals (ppm) Na, etc ~ %	Spectroscopy Residue on Ignition
Residual Solvents	ppm to 0.5%	Head-space GC
Particle Size	Case-by-case	Sieve, Laser Diffract.
Solid-State Form	Conforms/limit	Powder X-Ray; IR
Water Content	Few %	Chemical or wgt. loss
Microbial Limits Or Sterility	# of total aerobes and fungi per gram Pathogen (-)	Growth in special media

CMC Efficacy Concerns

- Generally not a reason for a “clinical hold”
- Assay uncertainty
- Uniformity of content
- Bioavailability

Rifampin Bioavailability



Use of Foreign Comparators in Clinical Trials*

Sample comment:

“The use of FDA-approved drug products provides assurance of drug quality. Where this is not possible and local products are used, documentation should be provided to show that the drug product is comparable in quality to the US product. Depending on the drug product, this could involve, for example, comparing impurity and dissolution profiles, and content uniformity.”

* Pre-IND approach recommended

Excipients – Quality Considerations

- Suitability for intended use (target organ/tissue)
- Functionality
- Compatibility with drug substance
- Safety/performance issues
- Source (USP/NF; FDA Inactive Ingredients Database)
- Excipients of Human or Animal Origins
- **Novel (new) Excipients***

*(1) Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients; (2) USP General Chapter <1074>

Container Closure System

- The sum of packaging components that together contain, protect, and deliver the dosage form
- IND should include a brief description of:
 - The packaging components
 - The assembled packaging system
 - Any precautions needed to ensure the protection and preservation of the drug substance and the drug product during the use in the clinical trials

Stability

- 21 CFR 312.23(a)(7)(ii): ...stability data are required in all phases of the IND to demonstrate that the drug substance and drug product are within acceptable chemical and physical limits for the planned duration of the proposed clinical investigation
- The amount of data will depend upon the duration of the proposed clinical study

Use of Stability Data

- To support investigational studies
- To ensure that the quality and safety of the investigational product is maintained throughout the clinical trial period
- To obtain impurity profile of the batches used during non-clinical toxicological studies

Expiration Dating Period

- Expiration dating period is not required for the investigational materials
- **Reconstituted products** are required to have a “use by” date
- CFR 211.137 (g). ---”where new drug products for investigational use are to be reconstituted at the time of dispensing, their labeling shall bear expiration information for the reconstituted drug product”

Clinical Trial Supplies*

- Examine container integrity on receipt
- Confirm label's 21 CFR 312.6 compliance
- Store at recommended conditions
- Document:
 - Receipt and storage
 - Condition of product on receipt
 - Dosing (including e.g. date & time, lot#, etc)
 - Reconciliation of all product at study conclusion
 - Records kept on-site

*See International Conference on Harmonisation of Technical Requirements for Registration Of Pharmaceuticals for Human Use Guidance E6, "Guideline for Good Clinical Practice"
<http://bit.ly/E6-GCPs> and 21 CFR 312.62

IND Guidance Sources

- Food Drug and Cosmetic Act
- Code of Federal Regulations (Title 21)
 - 21 CFR 312 (IND content and format)
 - 21 CFR 210 and 211 (CGMP)
- Guidance
 - FDA
 - ICH

FDA IND Guidance

- Phase 1 (<http://bit.ly/IND-Phase-1>)
- Phase 2 & 3 (<http://bit.ly/IND-Phase2-3>)
- Meetings (<http://bit.ly/IND-meetings>)
- MaPP 6030.1 (<http://bit.ly/IND-MaPP>)
- Exploratory IND (<http://bit.ly/Expl-IND>)
- GMP for Phase 1 (<http://bit.ly/IND-cGMP>)

Guidance for Industry: CGMP for Phase 1 Investigational Drugs (2008)

- Frequent questions about GMP expectations for Phase 1 trial materials; clear need for guidance
- Developed by Agency workgroup (CDER, CBER, ORA) composed of compliance staff, CMC reviewers, and investigators
- FDA's desire to ensure appropriate quality for early clinical trial material, without impeding drug development
- Articulates FDA's intent to implement an incremental approach to CGMP compliance for clinical investigational products
- FDA Guidance issued in 1991 "Preparation of Investigational New Drug Products (Human and Animal)" (reprinted November 1992) still applies to Phase 2 and Phase 3 clinical trial materials

Meetings

- Pre-IND Meetings
- EOP2 Meetings
 - Ensure that meaningful and adequate data are generated during Phase 3 studies
 - Identify safety issues, scientific issues and/or potential problems and address/resolve them prior to initiating Phase 3 studies
 - Identify potential roadblocks that could affect review of marketing application
 - Discuss and agree on plans/protocols relative to:
 - Regulations, guidances , and FDA policy
 - Quality by Design (QbD) approaches, if used
- Pre-NDA Meetings
 - Generally focusing on filing and format issues at least 6 months prior to NDA submission
 - Discussion of any problems that can lead to refuse-to-file recommendation or hinder the review process

Summary

- Sufficient CMC information should be provided in an IND to assure **identity, quality, purity and strength** of the study drug
- The level of CMC information increases as development progresses
- Critical CMC **safety** issues (including **impurities**) should be identified - safety concern is the primary reason for placing an IND on clinical hold based on CMC section
- Other **quality** issues should be considered and evaluated for INDs
- **CGMP** should be applied - Phase 1 drugs do not need full CGMP but do need good manufacturing controls
- Recommendations of ICH/FDA **guidances** and input from FDA are helpful during drug development



Thank you!